Citation

BibTex format

@article{Siddiqui:2026:10.1016/j.jacig.2026.100740,
author = {Siddiqui, S and Ding, B and Dolin, P and Edmonds, C and Jain, P and Rowell, J and Westerink, L and Lacetera, A and Suárez-Sánchez, P and Ariti, C and Podmore, B and Kitchin, Velarde A and Chen, SY},
doi = {10.1016/j.jacig.2026.100740},
journal = {J Allergy Clin Immunol Glob},
title = {Epidemiology, clinical management, and outcomes in patients with eosinophilic granulomatosis with polyangiitis in England: A retrospective observational cohort study.},
url = {http://dx.doi.org/10.1016/j.jacig.2026.100740},
volume = {5},
year = {2026}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: Data on the clinical burden of eosinophilic granulomatosis with polyangiitis (EGPA) are limited. OBJECTIVE: We sought to evaluate the epidemiology and clinical burden of EGPA in England using real-world evidence. METHODS: Patients diagnosed with EGPA between January 1, 2006, and February 28, 2019, who had ≥1 year of data before diagnosis (index date) were identified using the Clinical Practice Research Datalink Aurum database. Epidemiology, diagnosis, mortality, treatment, and clinical outcomes were assessed. RESULTS: The incident and prevalent EGPA cohorts comprised 486 and 729 patients, respectively. The overall incidence and prevalence of EGPA were 3.04 (95% CI: 2.77-3.32) cases per million person-years and 2.7 (95% CI: 2.5-2.9) cases per 100,000 persons, respectively. Overall, 76.3% and 26.1% of patients had a Five Factor Score of 0 on the 1996 and 2009 versions. In the incident cohort (mean age 57.9 ± 15.2 years), most patients (97.1%) had ≥1 comorbidity; 79.8% had asthma coded. The median time from first major manifestation to EGPA diagnosis was 44.0 (Q1-Q3: 20.0-56.0) months. The death rate was 37.1 per 1000 person-years (95% CI: 30.1-45.2); the standardized mortality ratio for all-cause deaths was 2.3 (95% CI: 1.9-2.8). The 5-year survival rate was 82.3% (95% CI: 78.1%-85.7%). Most patients (86.2%) received oral glucocorticoids, of whom 27.0% successfully tapered. Six months post index date, 26.1% of patients had a new EGPA manifestation. CONCLUSION: This study emphasizes the substantial clinical burden and reliance on glucocorticoids in EGPA, highlighting the need for improved diagnosis of this disorder.
AU  - Siddiqui,S
AU  - Ding,B
AU  - Dolin,P
AU  - Edmonds,C
AU  - Jain,P
AU  - Rowell,J
AU  - Westerink,L
AU  - Lacetera,A
AU  - Suárez-Sánchez,P
AU  - Ariti,C
AU  - Podmore,B
AU  - Kitchin,Velarde A
AU  - Chen,SY
DO  - 10.1016/j.jacig.2026.100740
PY  - 2026///
TI  - Epidemiology, clinical management, and outcomes in patients with eosinophilic granulomatosis with polyangiitis in England: A retrospective observational cohort study.
T2  - J Allergy Clin Immunol Glob
UR  - http://dx.doi.org/10.1016/j.jacig.2026.100740
UR  - https://www.ncbi.nlm.nih.gov/pubmed/42405355
VL  - 5
ER  -
Download